

## Product Information

## Anti-FLIP $\gamma/\delta$ , C-Terminal

Produced in Rabbit, Affinity Isolated Antibody

**F9925****Synonyms:** Anti-CLARP; Anti-CASH; Anti-FLAME-1; Anti-I-FLICE

### Product Description

Anti-FLIP $\gamma/\delta$ , C-Terminal is produced in rabbit using as immunogen a synthetic peptide corresponding to amino acids 191-209 of the C-terminal of human FLIP $\delta$ /FLIP $\gamma$ <sup>1</sup>.

Anti-FLIP $\gamma/\delta$ , C-Terminal detects FLIP $\gamma$  (35 kDa) and FLIP $\delta$ /FLIP $\gamma$  (25 kDa) by immunoblotting. The antibody reacts with human and mouse FLIP $\gamma/\delta$ .

Apoptosis plays an important role in tissue homeostasis and is related to many diseases. The death receptors induce apoptosis after triggering with ligand or agonistic antibodies.<sup>2</sup> The best-characterized member of the death receptor subfamily is CD95 (APO-1, Fas). Stimulation of CD95 leads to clustering of the receptor. This enables the adapter molecule FADD/MORT1<sup>3,4</sup> and the death protease caspase-8 (FLICE, MACH, MCH5),<sup>5-7</sup> to bind to the receptor via homophilic death domain and death effector domain (DED) interactions, respectively, forming the death-inducing signaling complex (DISC).<sup>8</sup> Recruitment of caspase-8 to the DISC leads to its proteolytic activation, which initiates a cascade of caspases, leading to apoptosis.<sup>9</sup>

Viral FLICE-inhibitory proteins (v-FLIPs)<sup>10-12</sup> are composed of two death effector domains, a structure resembling the N-terminal half of caspase-8. Via DED-DED interaction, v-FLIPs are recruited to the CD95 DISC,<sup>10</sup> preventing caspase-8 recruitment and processing and thereby CD95-induced apoptosis.

Human FLIP was identified by different groups and termed c-FLIP,<sup>1</sup> CASH,<sup>13</sup> Casper,<sup>14</sup> CLARP,<sup>15</sup> FLAME,<sup>16</sup> I-FLICE,<sup>17</sup> MRIT<sup>18</sup> and Usurpin.<sup>19</sup> On the mRNA level, c-FLIP seems to exist as multiple splice variants, FLIP $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$ , respectively.<sup>20,21</sup> Only two endogenous forms of the protein have been detected, c-FLIP<sub>long</sub> and c-FLIP<sub>short</sub>.<sup>13,14,19</sup> c-FLIP is structurally similar to caspase-8, since it contains two death effector domains and a caspase-like domain.

However, this domain lacks residues that are important for its catalytic activity, most notably the cysteine within the active site. The short form of c-FLIP structurally resembles v-FLIP. The role of c-FLIP in apoptosis signaling may be as pro-apoptotic molecule<sup>13,14,15,18</sup> or as an anti-apoptotic molecule.<sup>1, 13,14,16,17,19</sup> In addition, whether c-FLIP interacts with FADD and/or caspase-8 is not clear. Some groups have reported that c-FLIP can interact with both FADD and caspase-8,<sup>1, 13,14,16,18</sup> while others could only detect an interaction between c-FLIP and caspase-8.<sup>15,17,19</sup>

### Reagent

Solution in 0.01 M phosphate buffered saline, containing 0.02% sodium azide.

### Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

### Storage/Stability

Antibody can be stored at 2-8 °C for three months and at -20 °C for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

## Product Profile

**Immunoblotting:** the recommended dilution is 1:1000. A Jurkat (human T lymphocyte) cell lysate may be used as a positive control. Both 35 kDa and 25 kDa bands are detected.

**Immunocytochemistry:** 2 µg/mL

**Immunofluorescence:** 10 µg/mL

**Note:** In order to obtain best results and assay sensitivities of different techniques and preparations, we recommend determining optimal working dilutions by titration test.

## References

1. Irmiler, M., et al., *Nature*, **388**: 190-195 (1997).
2. Peter, M. E., et al., in *Apoptosis: Problems and Diseases* (Kumar, S., ed), Springer, Heidelberg pp. 25-63, (1998).
3. Boldin, M. P., et al., *J. Biol. Chem.*, **270**: 7795-7798 (1995).
4. Chinnaiyan, A. M., et al., *Cell*, **81**: 505-512 (1995).
5. Muzio, M., et al., *Cell*, **85**: 817-827 (1996).
6. Boldin, M. P., et al., *Cell*, **85**: 803-815 (1996).
7. Srinivasula, S. M., et al., *Proc. Natl. Acad. Sci. USA*, **93**: 14486-14491 (1996).
8. Kischkel, F. C., et al., *EMBO J.*, **14**: 5579-5588 (1995).
9. Medema, J. P., et al., *EMBO J.*, **16**: 2794-2804 (1997).
10. Thome, M., et al., *Nature*, **386**: 517-521 (1997).
11. Hu, S., et al., *J. Biol. Chem.*, **272**: 9621-9624 (1997).
12. Bertin, J., et al., *Proc. Natl. Acad. Sci. USA*, **94**: 1172-1176 (1997).
13. Goltsev, Y.V., et al., *J. Biol. Chem.*, **272**: 19641-19644 (1997).
14. Shu, H. B., et al., *Immunity*, **6**: 751-763 (1997).

15. Inohara, N., et al., *Proc. Natl. Acad. Sci. USA*, **94**: 10717-10722 (1997).
16. Srinivasula, S. M., et al., *J. Biol. Chem.*, **272**: 18542-18545 (1997).
17. Hu, S., et al., *J. Biol. Chem.*, **272**: 17255-17257 (1997).
18. Han, D. K., et al., *Proc. Natl. Acad. Sci. USA*, **94**: 11333-11338 (1997).
19. Dita, R. M., et al., *Cell Death Differ.*, **5**: 271-288 (1998).
20. Wallach, D., *Nature*, **388**: 123 (1997).
21. Tschopp, J., et al., *Curr. Opin. Immunol.*, **10**: 552-558 (1998).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

## Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

F9925dat Rev 06/21

**MILLIPORE  
SIGMA**